Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

https://www.globenewswire.com/news-release/2024/01/31/2821542/35575/en/Aptose-Announces-Closing-of-9-7-Million-Public-Offering-and-Concurrent-4-Million-Private-Placement-with-Hanmi-Pharmaceutical-Including-Full-Exercise-of-Over-Allotment-Option.html

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) —  Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the “Public Offering”) of 5,649,122 common shares of the Company (the “Common Shares”) and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. Each Common Share was sold with a warrant to purchase a Common Share (a “Warrant Share”) at an exercise price of US $1.71 per Warrant Share.

Read more at globenewswire.com

Related news for (APTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.